Nevertheless, we pursued CLL-1 as a CAR T cell target for JMML as it provides the possibility of improved safety over other targeted therapies (like CD33 and CD123) because of its reduced expression on normal HSCs48 (Supplementary Fig. 5). The gene discussed is CLEC12A; the disease is juvenile myelomonocytic leukemia.